辛妥珠单抗(INN:simtuzumab;开发代号:GS-6624)是一种人源化单克隆抗体,设计用于治疗纤维化。[1]它与LOXL2结合并充当免疫调节剂。[2][3]2016年1月,吉利德科学公司因缺乏疗效而终止了针对特发性肺纤维化(IPF)患者的II期临床研究。[4]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
- ^ Muir, Andrew J.; Levy, Cynthia; Janssen, Harry L. A.; Montano-Loza, Aldo J.; Shiffman, Mitchell L.; Caldwell, Stephen; Luketic, Velimir; Ding, Dora; Jia, Catherine; McColgan, Bryan J.; McHutchison, John G. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). 2019-02, 69 (2). ISSN 1527-3350. PMID 30153359. doi:10.1002/hep.30237.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2).
- ^ Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis. Gilead. 5 January 2016.